t
Feedback plc announced that on 21 December 2022, Non-Executive Chairman Rory Shaw purchased 22,270 Ordinary Shares at 89.8 pence, Non-Executive Director Philipp Prince purchased 4,531 Ordinary Shares at 89.9 pence, and Non-Executive Director Annemijn Eschauzier purchased 5,440 Ordinary Shares at 91.9 pence. The announcement also clarified a previous filing (5307K), stating the shares were "purchased" rather than "subscribed for," with a nominal value of "£0.50" rather than "0.50 pence," and were "Ordinary Shares" not "New Ordinary Shares."
| Date | 22 Dec 2022 |
| Time | 12:08:40 |
| Category | Director/PDMR dealings |
| ID | 6554K |
Feedback plc
Director Dealings
Further to announcement 5307K, made on 22 December 2022 at 07:00, outlining Director Dealings, the Company notes that, due to a clerical error, the shares were described as being "subscribed for" rather than "purchased" and the nominal value was given as "0.50 pence", not "£0.50". These were "Ordinary Shares" and not "New Ordinary Shares". There have been no other amends than clarification of purchasing of existing ordinary shares and amended nominal value.
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the frontline clinical technology company, announces the following Directors' dealings:
Rory Shaw, Non Executive Chairman, has purchased 22,270 Ordinary Shares at a price of 89.8 pence per Ordinary Share.
Philipp Prince, Non Executive Director, has purchased 4,531 Ordinary Shares at a price of 89.9 pence per Ordinary Share.
Annemijn Eschauzier, Non Executive Director, has purchased 5,440 Ordinary Shares at a price of 91.9 pence per Ordinary Share.
Details of the Ordinary Shares held by these Directors are detailed in the table below:
|
Director/ PDMR |
Position |
Existing interest in Ordinary Shares |
Ordinary Shares purchased |
Total beneficial interest in Ordinary Shares |
Total interest in Company's issued share capital |
|
Rory Shaw |
Non-Executive Chairman |
56,303 |
22,270 |
78,573 |
0.59% |
|
Philipp Prince |
Non-Executive Director |
20,232 |
4,531 |
24,763 |
0.19% |
|
Annemijn Eschauzier |
Non-Executive Director |
- |
5,440 |
5,440 |
0.04% |
The notification set out below, provides further details of such dealings:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Names
|
Rory Shaw Philipp Prince Annemijn Eschauzier |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Chairman Non-Executive Director Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Feedback plc |
|||
|
b)
|
LEI
|
213800UGOF2GT2U2RV90 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.50 each in Feedback plc |
|||
|
|
|
||||
|
Identification code |
GB00BJN59X09 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
89.8p |
22,270 |
|
|
|
|
|
89.9p |
4,531 |
|
|
|
|
|
91.9p |
5,440 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
n/a |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
21 December 2022 |
|||
|
f)
|
Place of the transaction |
XLON |
|||
Enquiries:
|
Feedback plc Tom Oakley, CEO Anesh Patel, CFO |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
|
Nick Rome/Joe Walker |
07748 325 236 or 07407 020 470 |
About Feedback
Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.
Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.
The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.